Institute Group Leaders awarded promotions in the University
We are delighted to announce that two of our Senior Group Leaders, Jason Carroll and Masashi Narita, have been promoted to professors in this years’ round of Senior Academic Promotions.

Both have been assigned to the Department of Oncology, where their professorships will take effect from 1 October 2019. They join 41 other world-leading researchers who have been promoted to professors across the University of Cambridge.
Jason Carroll has been promoted to Professor of Molecular Oncology. Carroll’s research at the Institute focuses on the oestrogen receptor, which switches on genes in breast cancer cells causing the cells to grow. By understanding how the oestrogen receptor switches genes on and how drugs like tamoxifen work to switch them off, the team hope to learn more about how cancers develop resistance to these drugs. This information can help to make better and more effective drugs for cancer treatments.
Masashi Narita has been promoted to the position of Professor of Senobiology. Narita’s team are studying how to permanently stop the growth of tumour cells. In response to internal and external stresses, cells can choose to either die or to stop cell division permanently in order to remove unhealthy cells. Permanently stopping cell growth causes many changes in cells, affecting gene expression and how proteins are processed within the cell. By understanding the mechanisms of these changes, the Narita Group are working to provide new and alternative tools to tackle cancers.
Related News
See all news-
Dr Guiping Wang appointed as a Junior Group Leader
18th May 2026
Dr Guiping Wang joins the Cancer Research UK Cambridge Institute as a Junior Group Leader, starting in September 2026.
Find out more -
Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research
14th May 2026
The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies.
Find out more -
Prof Sir Steve Jackson receives the 2026 Galen Medal in Therapeutics
14th May 2026
This award comes in recognition of his transformational work on the mechanisms of DNA repair, cell survival and the DNA-damage response (DDR), as well as for the development of the cancer-targeting drug Olaparib.
Find out more